November 16, 2016 - By Vivian Park · 0 Comments
The stock of SKYSTAR BIO PHARAMACEUTICAL COMPANY (OTCMKTS:SKBI) registered an increase of 1150% in short interest. SKBI’s total short interest was 10,000 shares in November as published by FINRA. Its up 1150% from 800 shares, reported previously. With 9,300 shares average volume, it will take short sellers 1 days to cover their SKBI’s short positions. The stock 0.02% or $0 on November 15, hitting $0.215. It is up 21.43% since April 14, 2016 and is downtrending. It has underperformed by 26.12% the S&P500.
Skystar Bio-Pharmaceutical Co., Ltd
Skystar Bio-Pharmaceutical Co., Ltd., incorporated on September 24, 1998, is a maker and distributor of veterinary medicines and healthcare products in China. The Firm develops, makes, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine (TCM); topicals, supplements, probiotics, and diagnostic kits and animal, animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets within China. The Firm operates four product lines: Probiotics, Veterinary Medicine, Veterinary Vaccines and Feed Additives.
More notable recent Skystar Bio-Pharmaceutical Company (OTCMKTS:SKBI) news were published by: Marketwired.com which released: “Skystar Bio-Pharmaceutical Announces Final Delisting From Nasdaq and Continued …” on February 26, 2016, also Marketwired.com with their article: “Skystar Bio-Pharmaceutical to File Financial Results for First Quarter of …” published on May 15, 2014, Streetinsider.com published: “Kandi Technologies Group (KNDI) Announces Two Key Executive Appointments” on November 14, 2016. More interesting news about Skystar Bio-Pharmaceutical Company (OTCMKTS:SKBI) were released by: Seekingalpha.com and their article: “The Perils Of Value Microcap Research And The Example Of Akers Biosciences” published on November 04, 2014 as well as Seekingalpha.com‘s news article titled: “Price-To-Book Values: Use Caution” with publication date: January 31, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Vivian Park